TY - JOUR
T1 - Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants
T2 - A randomized controlled trial
AU - Manzoni, Paolo
AU - Stolfi, Ilaria
AU - Messner, Hubert
AU - Cattani, Silvia
AU - Laforgia, Nicola
AU - Romeo, Mario G.
AU - Bollani, Lina
AU - Rinaldi, Matteo
AU - Gallo, Elena
AU - Quercia, Michele
AU - Maule, Milena
AU - Mostert, Michael
AU - Decembrino, Lidia
AU - Magaldi, Rosario
AU - Mosca, Fabio
AU - Vagnarelli, Federica
AU - Memo, Luigi
AU - Betta, Pasqua M.
AU - Stronati, Mauro
AU - Farina, Daniele
PY - 2012/1
Y1 - 2012/1
N2 - BACKGROUND: Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis in preterm very low birth weight (VLBW) neonates. METHODS: This is a secondary analysis of data from a multicenter randomized controlled trial where preterm VLBW neonates randomly received bLF (100 mg/day; group A1), bLF + Lactobacillus rhamnosus GG (10 6 colony-forming units per day; group A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates of fungal colonization, invasive fungal infection (IFI), and rate of progression from colonization to infection in all groups. RESULTS: This study included 472 neonates whose clinical, nutritional, and demographical characteristics were similar. Overall, the incidence of fungal colonization was comparable (17.6%, 16.6%, and 18.5% in A1, A2, and B, respectively; P = .89 [A1] and .77 [A2]). In contrast, IFIs were significantly decreased in A1 and A2 (0.7% and 2.0%, respectively) compared with B (7.7%; P = .002 [A1] and .02 [A2]), and this was significantly true both in
AB - BACKGROUND: Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis in preterm very low birth weight (VLBW) neonates. METHODS: This is a secondary analysis of data from a multicenter randomized controlled trial where preterm VLBW neonates randomly received bLF (100 mg/day; group A1), bLF + Lactobacillus rhamnosus GG (10 6 colony-forming units per day; group A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates of fungal colonization, invasive fungal infection (IFI), and rate of progression from colonization to infection in all groups. RESULTS: This study included 472 neonates whose clinical, nutritional, and demographical characteristics were similar. Overall, the incidence of fungal colonization was comparable (17.6%, 16.6%, and 18.5% in A1, A2, and B, respectively; P = .89 [A1] and .77 [A2]). In contrast, IFIs were significantly decreased in A1 and A2 (0.7% and 2.0%, respectively) compared with B (7.7%; P = .002 [A1] and .02 [A2]), and this was significantly true both in
KW - Candida
KW - Fungal sepsis
KW - Lactoferrin
KW - Prophylaxis
KW - VLBW neonates
UR - http://www.scopus.com/inward/record.url?scp=84855281430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855281430&partnerID=8YFLogxK
U2 - 10.1542/peds.2011-0279
DO - 10.1542/peds.2011-0279
M3 - Article
C2 - 22184648
AN - SCOPUS:84855281430
VL - 129
SP - 116
EP - 123
JO - Pediatrics
JF - Pediatrics
SN - 0031-4005
IS - 1
ER -